61 studies on Sermorelin curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 1,049 published Sermorelin COA source records from third-party laboratories, covering 399 publicly attributable vendor identities. Across 918 records with positive numeric purity, the arithmetic mean is 99.2%. 2 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 4 positive purity results are below 90%; 34 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-14. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 2 mg | $6.50 | $6.50–$6.50 | $3.25 | 1 source · 1 offer |
| 5 mg | $9.83 | $9.00–$10.50 | $1.97 | 3 sources · 3 offers |
| 10 mg | $15.50 | $14.50–$16.50 | $1.55 | 2 sources · 2 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-14. Aggregate calculated: 2026-10-18T04:26:34.361357+00:00. Calculation time is not a laboratory observation date.
Within that total, 249 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 26 | 99.24% | 0 of 21 (0.0%) 0 0% / not detected · 0 wrong compound · 5 unclassified | Reveal with Pro → | |
| #2 | 13 | 99.29% | 0 of 13 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 14 | 99.03% | 0 of 13 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #119432 (99.2%) · #120426 (99.69%) · #119967 (99.18%) · #119623 (99.61%) · #118949 (99.39%) · #118371 (99.64%)
The termination of this long-running study highlights the significant challenges inherent in conducting extensive, multi-year clinical research, particularly in broad observational contexts like endocrine diseases. Wh…
Understanding the precise role of GHRH (a hormone that stimulates GH release) in acromegaly is crucial for developing more targeted therapies. If endogenous GHRH significantly contributes to GH hypersecretion, then GH…
If GHRH were found to be effective, this research could pave the way for a novel therapeutic strategy to address age-related sleep disturbances, a widespread issue affecting millions. Successfully augmenting the GH-IG…
The premature termination of this study means a potential avenue for addressing age-related decline in muscle, bone, and fat health through GHRH remains unexplored by this particular trial. If successful, GHRH could h…
This research is critical for optimizing IVF protocols for a challenging patient population with diminished ovarian reserve, who often have lower success rates with conventional treatments. If the long Clomid protocol…
The premature termination of this study means a significant opportunity was missed to explore a potential therapeutic avenue for age-related decline. Given the widespread impact of low GH levels on muscle mass, bone d…
The intent behind this study highlights a critical challenge in endocrinology: the potential for significant inter-assay variability to compromise the accurate diagnosis and management of Growth Hormone (GH) disorders…
Targeting growth hormone pathways with GHRH offers a promising therapeutic strategy for managing abdominal obesity and its associated metabolic risks. If successful, this approach could provide a novel, physiological …
Understanding the sexually dimorphic nature of GH responses to GHRH could profoundly impact the diagnosis and management of Growth Hormone Deficiency. If confirmed, these findings could lead to the development of sex-…
This foundational Phase 1 study is critical because it provides essential data on how Tesamorelin behaves in HIV positive patients, a population with unique metabolic considerations. The successful characterization of…
The potential for Tesamorelin to augment exercise benefits in HIV-positive individuals is highly significant. If successful, this intervention could offer a novel and more effective strategy to combat frailty and phys…
Understanding Tesamorelin's short-term effects in healthy individuals is crucial for broadening its potential therapeutic applications beyond HIV-associated lipodystrophy. If Tesamorelin can safely enhance GH secretio…
The investigation into TH9507, a growth hormone-releasing factor (GRF) analogue, represents an important step in exploring novel therapeutic strategies for Type 2 Diabetes. GRF plays a role in metabolic regulation, an…
Understanding how growth hormone and growth hormone-releasing hormone impact GH secretion and glucose metabolism in HIV-infected patients is profoundly important for managing HIV lipodystrophy and its associated metab…
If the GHRH + Arginine test proves to have high specificity and sensitivity comparable to the ITT, it could represent a significant advancement in diagnosing AGHD. The ITT carries inherent risks due to induced hypogly…
The termination of this study represents a missed opportunity to gain crucial insights into the complex interplay between free fatty acids, obesity, and growth hormone secretion in a vulnerable pediatric population. H…
The withdrawal of this study highlights a persistent gap in research for effective treatments for TBI-related insomnia, a condition that significantly impacts the quality of life for service members and veterans. Had …
This Phase 1 study is crucial for establishing the foundational safety and preliminary efficacy signals for VRS-317, a potential long-acting treatment for Growth Hormone Deficiency. If successful in maintaining IGF-I …
The successful development of an oral growth hormone secretagogue like AEZS-130 for diagnostic purposes would represent a significant advancement in the management of Adult Growth Hormone Deficiency (AGHD). Such a tes…
The potential of TH9507 to selectively reduce visceral adipose tissue (VAT) in HIV patients with lipodystrophy is highly significant, as this fat accumulation is strongly linked to serious metabolic complications like…
For women struggling with poor ovarian response (POR), finding effective pre-treatment strategies is paramount to improving the success rates of IVF/ICSI and alleviating the significant emotional and financial burden …
If Growth Hormone Releasing Hormone (GHRH) were to demonstrate positive effects on cognitive function in Mild Cognitive Impairment (MCI), it would offer a novel and promising therapeutic strategy for a condition with …
**Clinicians and biohackers using sermorelin or GHRP-2** should recognize that abdominal fat is the dominant suppressor of combined secretagogue synergy — not simply age or low testosterone. **Reducing AVF before or a…
**TNBC patients currently have no approved targeted therapy**, making every mechanistically distinct druggable axis clinically meaningful. The finding that `SV1` — not the canonical `GHRH-R` — dominates receptor expre…
These findings are significant as they identify GHRH as a trophic hormone for bronchial neuroendocrine tumors, meaning it actively promotes their growth and activity. This discovery suggests that GHRH receptors could …
**GHRH antagonists such as MZ-5-156 may have therapeutic utility not only as antiproliferatives but as suppressors of iNOS-driven nitrosative and oxidative stress in lung cancer**, a dual mechanism that broadens their…
This review underscores that peptide-based therapies represent a crucial and evolving frontier in the management of advanced prostate cancer, offering targeted mechanisms to combat disease progression. The insights ga…
The study demonstrates that antagonizing the GHRH receptor with compounds like MIA-690 is a potent strategy for inhibiting melanoma growth. This is achieved by forcing the tumor suppressor protein `p27` back into the …
This research suggests that GHRH agonists like sermorelin and its more potent analogs could be a powerful therapeutic tool for improving recovery after a heart attack. For biohackers or clinicians exploring regenerati…
This study provides compelling evidence in a large animal model that GHRH agonists like the Sermorelin analog MR-409 can directly target the heart to promote structural repair after a heart attack. The significant red…
The findings position the GHRH analog **MR-409** as a potent mitogenic and anti-apoptotic agent for skin cells, suggesting it could be a valuable tool for enhancing tissue repair. For clinicians and individuals dealin…
These findings suggest that GHRH agonists like sermorelin or its analogs could be a promising therapeutic strategy for the early stages of diabetic retinopathy. By targeting antioxidant and anti-inflammatory pathways,…
These findings suggest that GHRH analogs like sermorelin may have beneficial effects on mood beyond their established roles, potentially by directly modulating neuroinflammation and monoamine neurotransmitter systems …
This research identifies the `GHRH-R/JAK2/STAT3` signaling axis as a key driver of acute anterior uveitis, establishing a new and specific therapeutic target. For clinicians and researchers, this suggests that drugs t…
This comprehensive review significantly expands our understanding of GHRH's multifaceted roles beyond its traditional endocrine function, particularly its involvement in cancer progression and lung inflammation. The c…
This research highlights a significant new therapeutic potential for GHRH antagonists, particularly MIA-602, in conditions involving blood-brain barrier dysfunction. Given their ability to protect brain microvascular …
These findings suggest GHRH agonists could be a novel and effective therapy for **heart failure with preserved ejection fraction (HFpEF)**, a condition with few treatment options. For clinicians and researchers, this …
This study proposes **sermorelin** as a potential new therapeutic avenue for recurrent glioma, one of the most difficult-to-treat cancers. For patients and clinicians dealing with aggressive, relapsed brain tumors—par…
These findings suggest a novel therapeutic avenue for optic neuropathies like glaucoma. While both GHRH agonists and antagonists showed some neuroprotective effects, the agonist **MR-409** uniquely synergized with the…
These findings suggest that GHRH receptor antagonism could be a novel and effective therapeutic strategy for mood disorders like anxiety and depression, and potentially for **PTSD**. For individuals exploring advanced…
Free, no account — handy when you're working with Sermorelin.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account